AbbVie Inc. (BMV:ABBV)

Market Cap	7.27T
Revenue (ttm)	1.09T
Net Income (ttm)	43.07B
Shares Out	n/a
EPS (ttm)	24.22
PE Ratio	168.81
Forward PE	16.60
Dividend	127.73 (3.11%)
Ex-Dividend Date	Oct 15, 2025

Volume	323
Average Volume	682
Open	4,109.57
Previous Close	4,097.00
Day's Range	4,109.57 - 4,109.57
52-Week Range	3,343.00 - 4,529.31
Beta	0.35
RSI	48.11
Earnings Date	Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD